• Biodesix will present new molecular residual disease data at the Association for Molecular Pathology meeting, Nov. 10-14, 2026, in Seattle.
• The tumor-informed research demonstrates personalized blood-based monitoring of complex tumor alterations using assays developed with Bio-Rad Laboratories.
• A tumor-naïve approach under development with Thermo Fisher Scientific requires no tumor tissue, potentially expanding access for patients with insufficient samples.
• Both programs are being validated with Memorial Sloan Kettering Cancer Center investigators, targeting deployment on partner platforms already installed in laboratories.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biodesix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090600PRIMZONEFULLFEED9872951) on November 09, 2026, and is solely responsible for the information contained therein.